INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.

MLA

Patt, Yehuda Z., et al. “INST OX-05-024: First Line Gemcitabine, Oxaliplatin, and Erlotinib for Primary Hepatocellular Carcinoma and Bile Duct Cancers: A Multicenter Phase II Trial.” Cancer Medicine, vol. 6, no. 9, Sept. 2017, pp. 2042–51. EBSCOhost, https://doi.org/10.1002/cam4.1138.

APA

Patt, Y. Z., Murad, W., Fekrazad, M. H., Baron, A. D., Bansal, P., Boumber, Y., Steinberg, K., Lee, S., Bedrick, E., Du, R., & Lee, F. C. (2017). INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer Medicine, 6(9), 2042–2051. https://doi.org/10.1002/cam4.1138

Chicago

Patt, Yehuda Z., Waheed Murad, Mohammed H. Fekrazad, Ari D. Baron, Pranshu Bansal, Yanis Boumber, Kim Steinberg, et al. 2017. “INST OX-05-024: First Line Gemcitabine, Oxaliplatin, and Erlotinib for Primary Hepatocellular Carcinoma and Bile Duct Cancers: A Multicenter Phase II Trial.” Cancer Medicine 6 (9): 2042–51. doi:10.1002/cam4.1138.